Kazia's precarious funding arrangement to be successful assumes a rising share price. As you are probably painfully aware, with final results about 19 months away the opposite is true. This funding issue and the trip feed dilution of Kazia at a very low price will be a continuing and ongoing drag on the share price.
Good luck everyone, these are just my thoughts not advice.
Cheers rroodd
Ann: GBM Agile opens to paxalisib in Europe, page-8
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)